Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An engineered TNFR1-selective human lymphotoxin-alpha mutant delivered by an oncolytic adenovirus for tumor immunotherapy.

Biochimica et biophysica acta. Molecular basis of disease - 1 Jun 2024

Cheng Yan, Liu Yu, Xu Dongge, Zhang Dan, Yang Yang, Miao Yuqing, He Susu, Xu Qing, Li Erguang

Abstract excerpt

Lymphotoxin α (LTα) is a soluble factor produced by activated lymphocytes which is cytotoxic to tumor cells. Although a promising candidate in cancer therapy, the application of recombinant LTα has been limited by its instability and toxicity by systemic administration. Secreted LTα interacts with several distinct receptors for its biological activities. Here, we report a TNFR1-selective human LTα mutant (LTα...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviridae
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphotoxin-alpha

Share to Mice, SCID

Share to Oncolytic Virotherapy

Share to Oncolytic Viruses

Share to Receptors, Tumor Necrosis Factor, Type I

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 38492783
DOI: 10.1016/j.bbadis.2024.167122

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An engineered TNFR1-selective human lymphotoxin-alpha mutant delivered by an oncolytic adenovirus for tumor immunotherapy.PMID 38492783Read ↗

An Attenuated Targeted-TNF Localizes to Tumors In Vivo and Regains Activity at the Site of Disease.Semantic proximity Read ↗

A novel immunogene therapy to cancer with high tumor selectivity and safetySemantic proximity Read ↗

Lysine-deficient lymphotoxin-α mutant for site-specific PEGylation.Semantic proximity Read ↗

Transgene expression of alpha tumor necrosis factor with mutations D142N and A144R under control of human telomerase reverse transcriptase promoter eradicates well-established tumors and induces long-term antitumor immunity.Semantic proximity Read ↗

Development and Characterization of a Potent Tumor Necrosis Factor-Alpha Blocking AgentSemantic proximity Read ↗

Regulating Cytokine Function Enhances Safety and Activity of Genetic Cancer TherapiesSemantic proximity Read ↗

Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.Semantic proximity Read ↗

Targeting transforming growth factor-β2 by antisense oligodeoxynucleotide accelerates T cell-mediated tumor rejection in a humanized mouse model of triple-negative breast cancerSemantic proximity Read ↗

DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model.Semantic proximity Read ↗

A YIGSR-containing novel mutein without the detrimental effect of human TNF-alpha of enhancing experimental pulmonary metastasis.Semantic proximity Read ↗

Enhancement of antitumor response of staphylococcal enterotoxin C2 mutant 2M-118 by promoting cell-mediated antitumor immunity.Semantic proximity Read ↗

Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.